Program
cannabis sativa flowering TOP
Also written as “Cannabis oil”, “MGCND00EP1” and “Medical Grade Cannabis oil”.
Its studies are mostly in Drug Resistant Epilepsy · Attention Deficit Disorder with Hyperactivity · Autistic Disorder · Hidradenitis Suppurativa, led by 5 companies.
Drug pageCannabis sativa flowering TOP: every studyMany companies study it; this page follows only the 6 they lead. All 15 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| TO Pharmaceuticals | 20 open or running | phase 2since Apr 24, 2019 | Apr 24, 2019 | none ahead |
| Brlev Agricultural Cropsits history only | 10 open or running | phase 2since Dec 30, 2021 | Dec 30, 2021 | none ahead |
| GreenCare Pharmaits history only | 11 open or running | phase 1since Jan 17, 2025 | Jan 17, 2025 | none ahead |
| MGC Pharmaceuticals d.o.oits history only | 10 open or running | phase 2since May 17, 2020 | May 17, 2020 | none ahead |
| New Age Venturesits history only | 10 open or running | phase 1since Jul 29, 2020 | Jul 29, 2020 | none ahead |
Also a collaborator on its studies: Bio-Sciences Pharma and KGK Science.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of TO Pharmaceuticals only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 24, 2019First studies: 2 phase 2 studiesFirst studyNCT05413187, NCT03929835
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 TO Pharmaceuticals leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05413187Autistic Disorder · Israel | 2 | Withdrawn | Sep 1, 2022 | 0 |
| NCT03929835Hidradenitis Suppurativa · Israel | 2 | Withdrawn | Sep 1, 2022 | 0 |
How it is read
Names in the registry
- “Cannabis oil”, 3 entries
- “MGCND00EP1”, 1 entry
- “Medical Grade Cannabis oil”, 1 entry
- “Cannabis Preparation”, 1 entry
Conditions, from the studies’ own filings
- Drug Resistant Epilepsy, 1 study
- Attention Deficit Disorder with Hyperactivity, 1 study
- Autistic Disorder, 1 study
- Hidradenitis Suppurativa, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.